Gilead Sciences Inc/ US3755581036 /
| 2024-12-20 10:26:40 AM | Chg. -1.44 | Volume | Bid5:30:00 PM | Ask5:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 87.05EUR | -1.63% | 14 Turnover: 1,218.70 |
-Bid Size: - | -Ask Size: - | 110.62 bill.EUR | - | - |
GlobeNewswire
08-08
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
08-08
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
GlobeNewswire
08-08
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
GlobeNewswire
08-06
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire
08-01
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
07-23
ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...
GlobeNewswire
07-15
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...
GlobeNewswire
07-01
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
07-01
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
06-28
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
06-26
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
06-26
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
06-18
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
06-10
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
